Apogee Therapeutics (APGE) is down -13.0%, or -$10.42 to $69.44.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Mizuho biotech analysts hold an analyst/industry conference call
- Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls
- Apogee Therapeutics price target raised to $116 from $109 at Craig-Hallum
- Aligos Therapeutics initiated with a Buy at UBS